Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

N/AEnrolling By InvitationNCT07594496

Mayo Clinic300 enrolled

Overview

This study evaluates the prevalence of cannabis withdrawal and the clinical manifestations of cannabis withdrawal syndrome in patients hospitalized for BMT or CAR-T therapy.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All adult patients admitted for BMT or CAR-T therapy Exclusion Criteria: * Individuals unable to provide informed consent

Locations (1)

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

Outcomes

Primary Outcomes

Prevalence of cannabis withdrawal

Descriptive statistics will be utilized to summarize cannabis withdrawal prevalence.

Time frame: Up to 1 year

Severity of withdrawal symptoms

Assessed by the Cannabis Withdrawal Scale (CWS), a self-report instrument used measures the intensity of 19 cannabis withdrawal symptoms over the last 24 hours. Each item is rated on a 10-point Likert scale where 0=not al all and 10=extremely. Items are rated twice, first for intensity of symptom and then for negative impact on daily activity. Withdrawal symptom scores range from 0 to 190, with higher scores reflecting greater intensity of withdrawal symptoms.

Time frame: Daily for first 4 days of hospitalization

Secondary Outcomes

Mortality Rate

Assessed for all-cause, in-hospital, and post-hospitalization mortality rates by review of the electronic medical record.

Time frame: Up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.